Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

BRAF inhibition efficacy in drug-refractory epilepsy
  • +5
  • Marta Perez-Somarriba,
  • Vicente Santa-María López ,
  • Ofelia Cruz Martinez,
  • Jordi Muchart,
  • Nagore Gene,
  • Jose Hinojosa,
  • Veronica Gonzalez,
  • Andres Morales La Madrid
Marta Perez-Somarriba
Hospital Sant Joan de Deu

Corresponding Author:[email protected]

Author Profile
Vicente Santa-María López
Hospital Sant Joan de Déu
Author Profile
Ofelia Cruz Martinez
Hospital Sant Joan de Deu
Author Profile
Jordi Muchart
Hospital Sant Joan de Deu
Author Profile
Nagore Gene
Hospital Sant Joan de Deu
Author Profile
Jose Hinojosa
Hospital Sant Joan de Déu
Author Profile
Veronica Gonzalez
Hospital Sant Joan de Deu
Author Profile
Andres Morales La Madrid
Hospital Sant Joan de Deu
Author Profile

Abstract

Low-grade gliomas (LGG) are the most frequent pediatric tumors associated with epilepsy. Molecular sequencing analyses have defined the genomic landscape of these tumors leading to the use of targeted therapies, which have proven to be efficacious. Ongoing clinical trials are testing the incorporation of these drugs, especially in unresectable LGG that progress after standard treatment. Nevertheless, this strategy is not extended in the field of tumor-induced epilepsy. We present a patient with drug-resistant epilepsy secondary to a BRAF V600E-mutated ganglioglioma treated with dabrafenib who showed a dramatic radiological and clinical response with marked improvement in her quality of life.